Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2018.9695

mmr-19-01-0638

Articles

Characterization of circRNA-associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation

Zhang

Yangyang

1 2 3 * Ke

Xianting

1 * Liu

Jingjing

1 Ma

Xiue

1 2 Liu

1 2 Liang

Dandan

1 2 Wang

Luxin

1 4 Guo

Changfa

5 Luo

Yiwei

1 6

1Key Laboratory of Arrhythmias of The Ministry of Education of China, East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China 2Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China 3Department of Cardiovascular Surgery, East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China 4Shanghai East Hospital of Clinical Medical College, Nanjing Medical University, Shanghai 200120, P.R. China 5Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China 6Department of Cardiology, East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China

Correspondence to: Dr Changfa Guo, Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, P.R. China, E-mail: guo.changfa@zs-hospital.sh.cn Dr Yiwei Luo, Key Laboratory of Arrhythmias of The Ministry of Education of China, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, P.R. China, E-mail: yiwei_luo1977@163.com *

Contributed equally

012019

26112018

19 1 638 650 28032018 13092018

2019

Circular RNAs (circRNAs) are non-coding RNAs forming closed-loop structures, and their aberrant expression may lead to disease. However, the potential network of circRNA-associated competing endogenous RNA (ceRNA) involved in nonvalvular persistent atrial fibrillation (NPAF) has not been previously reported. In the present study, four left atrial appendages (LAA) of patients with NPAF and four normal LAAs were examined via RNA sequencing, and their potential functions were investigated via bioinformatics analysis. The circRNA-enriched genes were analyzed using Gene Ontology (GO) categories, while the enrichment of circRNAs was detected via the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. A total of 296 significantly dysregulated circRNA transcripts were obtained, with 238 upregulated and 58 downregulated. A number of circRNAs were further confirmed using reverse transcription-quantitative polymerase chain reaction analysis. Furthermore, the more comprehensive circRNA-associated ceRNA networks were examined in patients with NPAF. GO categories and KEGG annotation analysis of circRNAs revealed that the circRNA-associated ceRNA networks were likely to influence AF though alterations in calcium and cardiac muscle contraction. The circRNA-associated ceRNA networks revealed that dysregulated circRNAs in NPAF may be involved in regulating hsa-microRNA (miR)-208b and hsa-miR-21. To the best of our knowledge, this study presents the circRNA-associated ceRNA networks in NPAF for the first time, which may have potential implications for the pathogenesis of AF. This study reveals a potential perspective from which to investigate circRNAs in circRNA-associated ceRNA networks (hsa_circRNA002085, hsa_circRNA001321) in NPAF, and provides a potential biomarker for AF.

NPAF RNA-seq circRNAs ceRNA pathway

Introduction

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia in humans, characterized by irregular and rapid electrical activity of the atria (1,2). In 2010, AF affected ~33.5 million people, causing ~5 million new cases each year worldwide (3,4). AF causes 130,000 mortalities/year in the USA (5) and affects 2–3% of the European population (4,6,7). The number of patients with AF is predicted to increase rapidly in the coming decades and to gradually reduce quality of life (8,9). In Asia, the number of patients with AF and AF-associated stroke is estimated to reach 72 million and 2.9 million by 2050, respectively (3,10). Warfarin is commonly applied to treat nonvalvular persistent atrial fibrillation (NPAF) and research on NPAF has been extensive (11,12), although the current treatment options remain inadequate. Thus, it is necessary to identify a novel biomarker for the prediction, diagnosis and treatment of NPAF.

Circular RNAs (circRNAs), non-coding RNAs identified in 1991 (13), regulate gene expression and act as microRNA (miRNA) ‘sponges’ by competing with endogenous RNA (ceRNA) networks to suppress specific miRNA activity (14,15). circRNAs are associated with numerous diseases and may serve an important role in diagnosis or pathogenesis (16,17). Previous studies have demonstrated that circRNA-miRNA-mRNA networks are likely to be involved in certain diseases (18,19). However, there is little research regarding the functions of circRNAs in AF, particularly NPAF. The present study aimed to identify a novel biomarker for diagnosis of AF.

Materials and methods <sec> <title>Ethics approval statement

Written informed consent was obtained from patients prior to collection of left atrial appendages (LAAs), which were abandoned due to surgical techniques. The present study was conducted in accordance with the Declaration of Helsinki, and all experimental procedures were approved by the Ethics Committee of Shanghai East Hospital (approval no. 040–2017) as per relevant guidelines and regulations (clinical research registration no. ChiCTR-RRC-17014230).

Clinical specimens

A total of four male patients with NPAF without valvular disease as an AF group, and four healthy male organ donors as a control group, were recruited between January 2016 and December 2017. AF specimens were collected from the LAAs of patients with NPAF during LAA excision along with surgical atrial fibrillation ablation. Normal LAAs were collected from healthy donors. Excised LAAs were stored in RNA later in −20°C prior to RNA extraction. Characteristics of the four patients are listed in Table I.

RNA extraction and qualification

Total RNA was isolated using TRIzol^® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's protocol, and dissolved in RNase-free water. RNA purity was assessed using a Nanodrop ND-2000 device (Thermo Fisher Scientific, Inc., Wilmington, DE, USA) with an absorbance (A)260/A280 of 1.8–2.0, and integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). The RNA integrity values of the RNAs obtained from the eight LAA specimens were 7.9, 7.7, 7.1, 7.3, 6.8, 7.2, 8.1 and 7.5, respectively.

RNA sequencing

Sequencing libraries were prepared as recommended by the VAHTS™ Total RNA-seq (H/M/R) Library Prep kit (Illumina, Inc., San Diego, CA, USA). Ribosomal RNA was removed using target-specific probes, RNase H and DNA polymerase I (Finnzyme; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and subsequently fragmented into pieces. Using reverse transcriptase and random primers, the RNA fragments were copied to the first strand of cDNA: 1 cycle of 25°C for 10 min; and 1 cycle of 50°C for 15 min and 85°C for 5 min, and the second strand was synthesized using DNA polymerase I, RNase H and dNTPs (dUTP, dATP, dGTP and dCTP; Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, single ‘A’ bases were added to the fragments of cDNA and then the adapter was ligated. To select the appropriate fragment size for sequencing, the library fragments were selected with VAHTSTM DNA Clean Beads (Vazyme Biotech Co., Nanjing, China). The second strand of cDNA was digested using an UDG (uracil-N-glycosylase) enzyme (Thermo Fisher Scientific, Inc.). Following cluster generation, 150-bp paired-end reads were produced by sequencing the libraries on the Illumina, Inc. Hiseq X10 platform.

Differential expression analysis

The expression levels of circRNAs were measured by RNA sequencing and expressed as ‘transcripts per kilobase million’. Differentially-expressed circRNAs were analyzed using DESeq2 based on the negative binomial distribution test, and the thresholds were P<0.05 and fold-change (FC) >2. P-values were calculated using a statistical algorithm (20).

Validation of circRNAs by reverse transcription-quantitative PCR (RT-qPCR)

A number of differential circRNAs were randomly selected to test the accuracy of the RNA sequencing data by RT-qPCR. Total RNA was reverse transcribed into cDNA using PrimeScript™ RT Reagent kit (Takara Bio, Inc., Shiga, Japan) according to standard procedures. A total reaction volume of 20 µl, including 1,000 ng RNA, 4 µl 5X PrimeScript RT Master Mix and RNase Free dH₂O. The thermocycling conditions were as follows: 37°C for 15 min, then 10 sec at 85°C. RT-qPCR was performed with a SYBR Green kit (Promega Corporation, Madison, WI, USA) in the QuantStudio™ 6 Flex system (Applied Biosystems; Thermo Fisher Scientific, Inc.), The reactions were incubated in 384-well plates at 50°C for 2 min, and 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min, followed by a dissociation curve. The internal reference was 18s rRNA (Applied Biosystems; Thermo Fisher Scientific, Inc.). Relative expression was quantified using the 2^−ΔΔCq method (21). The primers are listed in Table II.

Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis

The differential or target genes of circRNAs were estimated and determined using GO enrichment analysis at the perl module (GO: TermFinder, http://search.cpan.org/dist/GO-TermFinder/) The KEGG enrichment of target genes of differential circRNAs was tested using R functions (22) (P hyper and Q value). The significantly-enriched GO terms and KEGG pathways met the criterion of corrected P<0.05.

circRNA-ceRNA interaction prediction

The circRNA-miRNA interactions were predicted using TargetScan 6.0 (http://www.targetscan.org/vert_60/), which identifies miRNA targets and determines whether or not a given target is conserved across a given set of species. The sequences of circRNAs were predicted as miRNA binding seed sequence sites using potential miRNA response elements.

Statistical analysis

Statistical analyses was conducted using SPSS 19.0 software (IBM Corp., Armonk, NY, USA). When comparing two groups of profile differences, the fold-change (i.e. the ratio of the group averages) between the groups for each circRNA was computed. The differential expression of circRNAs was assessed using a Student's unpaired t-test. Error bars in the figures represent the means ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Overview of RNA-seq

No significant between-group difference was identified in the expression levels of 15,777 circRNAs. In total, 296 differential circRNAs were identified with FC>2 and P<0.05. Among them, 238 were upregulated and 58 were downregulated in NPAF tissues compared with the controls (Figs. 1 and 2). The upregulated circRNAs (data not shown; available at http://1drv.ms/w/s!Al7sl_MjqbmWgQDki8ZjwTQd2j0H) with ‘FC >2’ and downregulated circRNAs (data not shown; available at http://1drv.ms/w/s!Al7sl_MjqbmWgQEKE-v8hCjzTevu) are listed. A number of the circRNAs were used in the subsequent analysis.

Validation of circRNAs by RT-qPCR

A total of six dysregulated circRNAs were randomly selected as representatives to validate the RNA sequencing data by RT-qPCR, and the primers are listed in Table II. All circRNAs were well-validated by qPCR, and the directions of the changes were consistent with the RNA-seq data (Fig. 3). The RT-qPCR data suggested the RNA-seq-identified circRNAs are reliable and require further research.

Functional enrichment analysis: GO and KEGG pathway analysis

The differential circRNAs were annotated with GO, and were identified to be involved in the following functions: Cell component, biological process and molecular function (Fig. 4). GO analysis revealed that a number of functional pathways were enriched. Some of the top 10 terms were as follows: ‘Voltage-gated calcium channel activity is involved in AV node cell action potential’ in cell component GO (no. 0086056); ‘cardiac muscle contraction is regulated by calcium ion signaling’ in bioprocess GO (no. 0010882); ‘release of sequestered calcium ion into cytosol is regulated by sarcoplasmic reticulum’ in bioprocess GO (no. 0010880); and ‘regulation of cardiac muscle cell action potential is involved in regulation of contraction’ in bioprocess GO (no. 0098909), which were the most closely associated with AF. These criteria from the GO analysis were also applied to the KEGG enrichment analysis. The top 20 KEGG pathway analysis demonstrated that the most significant pathways involved in AF were ‘arrhythmogenic right ventricular cardiomyopathy’ (no. ko05412) and ‘cardiac muscle contraction’ (no. ko04260; Fig. 5).

Construction of circRNA-ceRNA interaction network

To analyze the interaction between differential circRNAs and ceRNAs, a ceRNA network in NPAF was investigated using RNA sequencing data. To examine which circRNAs were vital for NPAF progression, nine differential circRNAs were selected from those with calcium-associated parental genes. Complete sequences of hsa_circRNA-011785, −001321, −003878, −002085, −003884, −003876, −007410, −007411 and −004558 are listed in Table III. Details are provided in Table IV. A representative network of circRNAs and miRNAs is presented in Fig. 6. The interactions between hsa_circRNA002085 and hsa-miRNA (miR)-21, and between hsa_circRNA001321 and hsa-miR-1, suggest the possibility of an NPAF regulatory mechanism.

Discussion

In total, 296 differential circRNAs were identified between NPAF tissues and the controls (FC>2; P<0.05), including 238 upregulated circRNAs and 58 downregulated circRNAs. To validate the RNA sequencing data, six representative dysregulated circRNAs (hsa_circRNA-011430, −015317, −016587, −003585, −015019 and −003126) were selected. The RT-qPCR results suggested that the RNA sequencing-identified circRNAs are reliable and merit further research. The significantly dysregulated circRNAs in patients with NPAF may serve a regulatory role in the mechanism of AF progression.

Unlike linear RNAs, circRNAs are covalently linked to form closed-loop structures without 5′ caps or 3′ tails (18,23–25). In circRNAs, a downstream splice donor is joined by ‘back-splicing’ to the upstream splice acceptor (17,26,27). circRNAs are associated with, and serve important roles in the diagnosis and pathogenesis of, numerous diseases (16,17), including colorectal cancer (28), breast cancer (29) and gastric cancer (30). Furthermore, circRNAs are able to upregulate the expression levels of fibrosis-associated genes in cardiac fibroblasts (31). Other studies have reported that a circRNA-ceRNA network may be present in certain diseases (18,19). However, the circRNAs and circRNA-ceRNA network leading to AF remain to be elucidated.

AF remains a common cause of stroke, heart failure and cardiovascular mortality worldwide. AF may occur idiopathically, which is associated with familial inherent specific genetic mutations (32). Certain mechanisms leading to AF are primarily associated with the remodeling of ion channel functions, including those of K⁺ channels, and cellular Ca²⁺ handling and release (33–36). Other mechanisms of AF include mutations and the abnormal expression of genes encoding cardiac ion channels, including potassium voltage-gated channel subfamily Q member 1, potassium voltage-gated channel subfamily E regulatory subunit 2, potassium voltage-gated channel subfamily J member 2 (KCNJ2) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2A (SERCA2) (36).

For instance, calcium gene expression was identified to be abnormal in AF (37), and was hypothesized to contribute to the propensity for structural remodeling in AF. The calcium signaling pathway is essential in the electrical remodeling of AF and may induce the recurrence of AF (37). Abnormalities in intracellular Ca²⁺ handling are crucially involved in AF-initiated focal activity and perpetuation through rapidly firing foci and reentry (37).

GO analysis performed using differential circRNAs between the NPAF and control groups demonstrated that a number of functional pathways were enriched. The primary cell component was GO (no. 0086056) ‘voltage-gated calcium channel activity is involved in AV node cell action potential’. The main bioprocesses were GO (no. 0010882) ‘cardiac muscle contraction is regulated by calcium ion signaling’, GO (no. 0010880) ‘release of sequestered calcium ion into cytosol is regulated by sarcoplasmic reticulum’ and GO (no. 0098909) ‘regulation of cardiac muscle cell action potential is involved in regulation of contraction’. The specific genomes were ‘CACNB2, CACNA1C’ (GO:0086056); ‘SLC8A1, ATP2A2, CACNA1C, ANK2, RYR2’ (GO:0010882); ‘DHRS7C, CACNA1C, SLC8A1, RYR2, ANK2’ (GO:0010880); ‘CACNA1C, ATP2A2, RYR2, ANK2’ (GO:0098909). These genes are primarily involved in Ca²⁺ channels and may be the most closely associated with AF. A total of two of the most significant top 20 KEGG pathways were ‘arrhythmogenic right ventricular cardiomyopathy’ (no. ko05412) and ‘cardiac muscle contraction’ (no. ko04260), which were also associated with AF. Differential expression of circRNAs may be affected by AF and atrial remodeling. The present study identified a number of differential circRNAs in AF.

The circRNA-ceRNA interactions were constructed to examine which circRNAs serve important roles in NPAF progression. A total of nine differential circRNAs (hsa_circRNA-011785, −001321, −003878, −002085, −003884, −003876, −007410, −007411 and −004558) from calcium-associated parental genes were selected. miRNAs serve multiple roles in atrial fibrillation, including regulating electrical remodeling by targeting the genes involved in different ion channels, and regulating structural remodeling in cardiac tissues by increasing cardiac fibrosis or apoptosis. Different miRNAs have been demonstrated to be upregulated or downregulated in patients with AF (21), and may target different genes to regulate cardiac function. Different miRNAs may target single genes and serve similar roles, including repressing I_K1 (potassium current) by targeting KCNJ2 via miR-1 and miR-26 (22,38). In the present study, certain circRNAs were also dysregulated in AF, which might indicate an association. The interactions between hsa_circRNA004558 and miR-208b, between hsa_circRNA002085 and hsa-miR-21, and between hsa_circRNA001321 and hsa-miR-1 may suggest a possible regulatory mechanism in AF. For instance, miR-208b was demonstrated to be upregulated in patients with AF and an ovine model. Furthermore, a high miR-208b level was demonstrated to increase MYH7 expression and alter the subcellular localization of connexin43 (39). miR-208b has been reported to reduce the expression levels of CaV1.2 and SERCA2, which further reduce L-type Ca²⁺ current density and sarcoplasmic reticulum Ca²⁺ load/release, respectively (39). These alterations are hallmarks of atrial remodeling during AF (40). miR-21 is reportedly associated with atrial fibrosis regulation in AF, which inhibits the proliferation of cardiac fibroblasts by inactivating the transforming growth factor (TGF)-β1/mothers against decapentaplegic homolog (Smad)2 signaling pathway (41).

miR-21-3p may regulate sepsis-associated cardiac dysfunction and the development of cardiac hypertrophy. When miR-21-3p is inhibited, such diseases may be treated via a protective strategy (42,43). The upregulated inward rectifier currents (I_K1) associated with the electrical remodeling of AF are required to maintain AF. Additionally, miR-1 expression is downregulated in patients with AF, which may increase the levels of inwardly rectifying potassium channel (Kir)2.1 subunits and I_K1 (44,45). miR-4732-3p is targeted by three circRNAs (hsa_circRNA-003876, −003878 and −003884), and represses TGF-β signaling by targeting Smad2 and Smad4, and promoting cell proliferation (46). The TGF-β and Smad signaling pathways serve essential roles in atrial fibrosis.

The results of the present study provide a potential novel insight into the molecular mechanisms and therapeutic implications of AF. The circRNA-ceRNA interactions identified may act as biosignatures for AF, and provide evidence for identifying a novel agent for the diagnosis and gene-targeted therapy of AF.

The current study has a few limitations. Firstly, though the effects of clinical patient characteristics (e.g. comorbidities, duration of AF and use of drugs) on the analysis of the RNA network were considered during patient selection, it is not possible to disregard these effects. Secondly, the circRNA data for NPAF and normal tissues were obtained from RNA sequencing, although further validation is required, including through the use of knockdown and overexpression experiments on target circRNAs and miRNAs.

Acknowledgements

Not applicable.

Funding

The present study was funded by the General Program of the National Natural Science Foundation of China (grant nos. 81500252 and 81770267, to DL), and the Outstanding Young Talent Training Program of Shanghai Municipal Commission of Health and Family Planning (grant no. 2017YQ045, to DL).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

CG and YLu conceived and designed the experiments. YZ, XK and JL performed the experiments. XM, YLi, DL and LW analyzed the data. YZ, CG and YLu wrote the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent from patients was obtained prior to collection of the left atrial appendages, which were abandoned due to the surgical technique. The study was approved by the ethics committees (no. 040-2017) in accordance with the relevant guidelines and regulations (clinical research registration no. ChiCTR-RRC-17014230). The patients provided written informed consent.

Patient consent for publication

The patients provided written informed consent for publication.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

circRNA

circular RNA

ceRNA

competing endogenous RNA

NPAF

nonvalvular persistent atrial fibrillation

LAA

left atrial appendages

Gene Ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

atrial fibrillation

fold-change

RT-qPCR

reverse transcription-quantitative polymerase chain reaction

TGF-β1

transforming growth factor-β1

References 1

Nattel

New ideas about atrial fibrillation 50 years on

Nature4152192262002

10.1038/415219a

11805846

Gudbjartsson

Arnar

Helgadottir

Gretarsdottir

Holm

Sigurdsson

Jonasdottir

Baker

Thorleifsson

Kristjansson

Variants conferring risk of atrial fibrillation on chromosome 4q25

Nature4483533572007

10.1038/nature06007

17603472

Dong

Is atrial fibrillation a preventable disease?

J Am Coll Cardiol69196819822017

10.1016/j.jacc.2017.02.020

28408027

Chugh

Havmoeller

Narayanan

Singh

Rienstra

Benjamin

Gillum

Kim

McAnulty

JrZheng

Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study

Circulation1298378472014

10.1161/CIRCULATIONAHA.113.005119

24345399

Hijazi

Oldgren

Lindbäck

Alexander

Connolly

Eikelboom

Ezekowitz

Held

Hylek

Lopes

A biomarker-based risk score to predict death in patients with atrial fibrillation: The ABC (age, biomarkers, clinical history) death risk score

Eur Heart J394774852018

10.1093/eurheartj/ehx584

29069359

Schnabel

Yin

Gona

Larson

Beiser

McManus

Newton-Cheh

Lubitz

Magnani

Ellinor

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study

Lancet3861541622015

10.1016/S0140-6736(14)61774-8

25960110

4553037

Kirchhof

The future of atrial fibrillation management: Integrated care and stratified therapy

Lancet390187318872017

10.1016/S0140-6736(17)31072-3

28460828

Kotecha

Calvert

Deeks

Griffith

Kirchhof

Lip

Mehta

Slinn

Stanbury

Steeds

Townend

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial

BMJ Open7e0150992017

10.1136/bmjopen-2016-015099

28729311

5588987

Kirchhof

Benussi

Kotecha

Ahlsson

Atar

Casadei

Castella

Diener

Heidbuchel

Hendriks

2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Europace18160916782016

10.1093/europace/euw295

27567465

Chiang

Wang

Lip

Stroke prevention in atrial fibrillation: An Asian perspective

Thromb Haemost1117897972014

10.1160/TH13-11-0948

24500243

Fauchier

Philippart

Clementy

Bourguignon

Angoulvant

Ivanes

Babuty

Bernard

How to define valvular atrial fibrillation?

Arch Cardiovasc Dis1085305392015

10.1016/j.acvd.2015.06.002

26184867

Boriani

Cimaglia

Fantecchi

Mantovani

Ziacchi

Valzania

Martignani

Biffi

Diemberger

Non-valvular atrial fibrillation: Potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants

J Cardiovasc Med (Hagerstown)164914962015

10.2459/JCM.0000000000000236

25575278

Nigro

Cho

Fearon

Kern

Ruppert

Oliner

Kinzler

Vogelstein

Scrambled exons

Cell646076131991

10.1016/0092-8674(91)90244-S

1991322

Hansen

Jensen

Clausen

Bramsen

Finsen

Damgaard

Kjems

Natural RNA circles function as efficient microRNA sponges

Nature4953843882013

10.1038/nature11993

23446346

Memczak

Jens

Elefsinioti

Torti

Krueger

Rybak

Maier

Mackowiak

Gregersen

Munschauer

Circular RNAs are a large class of animal RNAs with regulatory potency

Nature4953333382013

10.1038/nature11928

23446348

Cortés-López

Miura

Emerging functions of circular RNAs

Yale J Biol Med895275372016

28018143

5168830

Zhang

Xiong

Huang

Liao

Zhu

Wang

Deep circular RNA sequencing provides insights into the mechanism underlying grass carp reovirus infection

Int J Mol Sci18piiE19772017

10.3390/ijms18091977

28906455

Zhang

Zhu

Feng

Zhang

Characterization of circRNA-associated-ceRNA networks in a senescence-accelerated mouse prone 8 brain

Mol Ther25205320612017

10.1016/j.ymthe.2017.06.009

28669840

5589091

Nan

Chen

Zhang

Liu

Yang

Wang

Yang

Jiang

A novel regulatory network among LncRpa, CircRar1, MiR-671 and apoptotic genes promotes lead-induced neuronal cell apoptosis

Arch Toxicol91167116842017

10.1007/s00204-016-1837-1

27604105

Audic

Claverie

Self-identification of protein-coding regions in microbial genomes

Proc Natl Acad Sci USA9510026100311998

10.1073/pnas.95.17.10026

9707594

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Lin

Deng

Shen

Fang

Fei

Zhao

Zhang

Pan

Xie

Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells

J Transl Med142252016

10.1186/s12967-016-0977-7

27465405

4964270

Yang

Wang

Gao

Shang

Sun

Dou

Circular RNA: A new star of noncoding RNAs

Cancer Lett3651411482015

10.1016/j.canlet.2015.06.003

26052092

Jeck

Sharpless

Detecting and characterizing circular RNAs

Nat Biotechnol324534612014

10.1038/nbt.2890

24811520

4121655

Chen

Yang

Regulation of circRNA biogenesis

RNA Biol123813882015

10.1080/15476286.2015.1020271

25746834

4615371

Jeck

Sorrentino

Wang

Slevin

Burd

Liu

Marzluff

Sharpless

Circular RNAs are abundant, conserved, and associated with ALU repeats

RNA191411572013

10.1261/rna.035667.112

23249747

3543092

Starke

Jost

Rossbach

Schneider

Schreiner

Hung

Bindereif

Exon circularization requires canonical splice signals

Cell Rep101031112015

10.1016/j.celrep.2014.12.002

25543144

Guo

Zhu

Feng

Shao

Wan

Huang

Comprehensive profile of differentially expressed circular RNAs reveals that hsa_circ_0000069 is upregulated and promotes cell proliferation, migration, and invasion in colorectal cancer

Onco Targets Ther9745174582016

10.2147/OTT.S123220

28003761

5158168

Galasso

Costantino

Pasquali

Minotti

Baldassari

Corrà

Agnoletto

Volinia

Profiling of the predicted circular RNAs in ductal in situ and invasive breast cancer: A pilot study

Int J Genomics201645038402016

10.1155/2016/4503840

27965971

5124670

Chen

Zheng

Bao

Chen

Lyu

Zheng

Long

Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer

Cancer Lett3882082192017

10.1016/j.canlet.2016.12.006

27986464

Tang

Zhang

Huang

Zhu

Xiao

Zhang

Lin

Zheng

Yang

CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts

Sci Rep7403422017

10.1038/srep40342

28079129

5228128

Woods

Olgin

Atrial fibrillation therapy now and in the future: Drugs, biologicals, and ablation

Circ Res114153215462014

10.1161/CIRCRESAHA.114.302362

24763469

4169264

Brundel

Van Gelder

Henning

Tuinenburg

Wietses

Grandjean

Wilde

Van Gilst

Crijns

Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: Differential regulation of protein and mRNA levels for K+ channels

J Am Coll Cardiol379269322001

10.1016/S0735-1097(00)01195-5

11693772

Santulli

D'ascia

Development of atrial fibrillation in recipients of cardiac resynchronization therapy: The role of atrial reverse remodelling

Can J Cardiol28245.e17e182012

10.1016/j.cjca.2011.11.001

Xie

Santulli

Guo

Gao

Chen

Marks

Imaging atrial arrhythmic intracellular calcium in intact heart

J Mol Cell Cardiol641201232013

10.1016/j.yjmcc.2013.09.003

24041536

4387875

Andrade

Khairy

Dobrev

Nattel

The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms

Circ Res114145314682014

10.1161/CIRCRESAHA.114.303211

24763464

Dobrev

Nattel

Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics

J Cardiovasc Pharmacol522932992008

10.1097/FJC.0b013e318171924d

18791467

Luo

Pan

Shan

Xiao

Sun

Wang

Lin

Xiao

Maguy

MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation

J Clin Invest123193919512013

10.1172/JCI62185

23543060

3635715

Cañón

Caballero

Herraiz-Martinez

Pérez-Hernández

López

Atienza

Jalife

Hove-Madsen

Delpón

Bernad

miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation

J Mol Cell Cardiol991621732016

10.1016/j.yjmcc.2016.08.012

27545043

Lai

Lin

Tsai

Chen

Huang

Tseng

Lien

Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: An insight into the mechanism of atrial electrical remodeling

J Am Coll Cardiol33123112371999

10.1016/S0735-1097(99)00008-X

10193721

Tao

Zhang

Yang

Shi

MicroRNA-21 via dysregulation of WW domain-containing protein 1 regulate atrial fibrosis in atrial fibrillation

Heart Lung Circ271041132018

10.1016/j.hlc.2016.01.022

28495464

Wang

Bei

Shen

Huang

Shi

Zhang

Sun

Chen

Yang

miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2

J Mol Cell Cardiol9443532016

10.1016/j.yjmcc.2016.03.014

27033308

Yan

Chen

Gong

Yin

Zhou

Chaugai

Wang

miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8

Cardiovasc Res1053403522015

10.1093/cvr/cvu254

25504627

Girmatsion

Biliczki

Bonauer

Wimmer-Greinecker

Scherer

Moritz

Bukowska

Goette

Nattel

Hohnloser

Ehrlich

Changes in microRNA-1 expression and I-K1 up-regulation in human atrial fibrillation

Heart Rhythm6180218092009

10.1016/j.hrthm.2009.08.035

19959133

Ehrlich

Inward rectifier potassium currents as a target for atrial fibrillation therapy

J Cardiovasc Pharmacol521291352008

10.1097/FJC.0b013e31816c4325

18670367

Doss

Corcoran

Jima

Telen

Dave

Chi

A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes

BMC Genomics169522015

10.1186/s12864-015-2156-2

26573221

4647483

Figure 1.

Volcano plot of circRNAs between the NPAF and control groups illustrates the distribution and number of circRNAs. Red and green represents upregulated and downregulated circRNAs, respectively, with fold-change >2 and P<0.05. Blue represents unaltered circRNAs. NPAF, nonvalvular persistent atrial fibrillation; circRNA, circular RNA.

Figure 2.

Heatmap of differentially-expressed circRNAs between the NPAF and control groups. The expression levels of circRNAs are represented by colored bars. The red and green color represents upregulated and downregulated circRNAs, respectively. Higher intensity of color indicates a greater degree of up- or downregulation. AF, NPAF; Ctrl, control. NPAF, nonvalvular persistent atrial fibrillation; circRNA, circular RNA.

Figure 3.

Validation of differentially expressed circRNAs between the NPAF and control groups by reverse transcription-quantitative polymerase chain reaction. A total of six circRNAs were validated and 18s was used as the internal control. The validation rate of the six circRNAs was approaching 100%, demonstrating that the circRNA sequencing data were reliable. *P<0.05, **P<0.01, ***P<0.001 vs. control. NPAF, nonvalvular persistent atrial fibrillation; circRNA, circular RNA.

Figure 4.

GO annotations and enrichment analysis of the differentially expressed circRNAs between the NPAF and control groups. The differentially expressed circRNAs between the NPAF and control groups were annotated with respect to three components (cellular component, biological process and molecular function). Q<0.05. GO, gene ontology; NPAF, nonvalvular persistent atrial fibrillation; circRNA, circular RNA.

Figure 5.

Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the differentially expressed circRNAs between the nonvalvular persistent atrial fibrillation and control groups. The number of genes is represented by the size of the circle, and the Q-value is represented by the color. circRNA, circular RNA.

Figure 6.

cirRNA-miRNA networks between the NPAF and control groups. Red and blue represents circRNAs and miRNAs, respectively. miRNA/miR, microRNA; circRNA, circular RNA.

Table I.

Demographic characteristics of patients.

No.	Age, years	Sex	NYHA	INR	Coronary artery	Disease complications	Duration of AF, years	Drug treatments
1	64	Male	II–III	3.38	Negative	Type II diabetes	2	Warfarin, furosemide, spironolactone and Cordarone
2	76	Male	II–III	0.92	Negative	Negative	3	Warfarin, Cordarone, spironolactone, furosemide and Betaloc
3	69	Male	II–III	2.03	Negative	Negative	4	Warfarin, Betaloc, furosemide, spironolactone and Cordarone
4	60	Male	II–III	2.00	Negative	Negative	2	Warfarin, furosemide and spironolactone

NYHA, New York Heart Association; INR, International Normalized Ratio; AF, atrial fibrillation.

Table II.

The list of circRNAs qRT-PCR primers between NPAF and controls.

CircRNA	Forward primer	Reverse primer
hsa_circRNA011430	CGAGCAGTACCCCACAATGG	TCTGTTGGCATGCTGCTGAA
hsa_circRNA015317	ATTAGGCAGACTCTTCAAAACGC	AAACCCCCACCCACAAAGCA
hsa_circRNA016587	TAGGCACAGCTCCTCCAGAT	TGTGAGATGCTTCACTGCATTC
hsa_circRNA003585	GCTGCCCAATGATCTGCTTG	CCCTGCTTGCAGCTGTAGAAT
hsa_circRNA015019	GGAGCCAAAGCCTAATCCGC	CTGCTGCCAAGGCATACTCA
hsa_circRNA003126	ATGGACTGGCGGATCAAGGA	TGGCCACCAGTCACAAGGTA

Table III.

Complete sequence of differentially expressed circRNAs between the NPAF and control groups.

circ_ID	Sequence
hsa_circRNA011785	AAAATGTAGGCCGGTTAATCACTCCTGCCAAAAAGCTTGAAGATACAATACGTCTTGCTGAACTAGTCATTGAAGTTCTTCAGCAAAATGAGGAGCACCACGCAGAGCCACATGTTGATAAAGGAGAAGCCTTTGCGTGGTGGTCAGATTTAATGGTGGAGCATGCGGAGACGTTCCTGTCACTCTTTGCAGTAGACATGGATGCAGCCTTAGAGGTGCAACCTCCAGACACATGGGACAGTTTTCCACTATTTCAGCTGCTGAATGATTTTCTCCGTACTGACTATAATTTGTGCAATGGAAAATTTCACAAACACCTGCAAGACCTGTTTGCCCCACTTGTTGTTAGATATGTGGATCTGATGGAGTCCTCAATTGCACAATCCATTCACAGGGGCTTTGAGCGGGAGTCATGGGAACCAGTCAAGAGTTTAACCAGTAACCTACCCAATGTGAACCTACCCAATGTGAACCTTCCCAAAGTACCAAATCTACCAGTTAACATCCCTCTAGGCATCCCACAAATGCCTACTTTTTCGGCACCGTCATGGATGGCTGCTATATATGATGCGGATAATGGGTCAGGCACCTCAGAAGATCTGTTTTGGAAACTTGACGCCCTTCAGACCTTCATTCGGGACCTGCACTGGCCTGAAGAAGAGTTTGGAAAGCACCTGGAACAACGGCTGAAGTTGATGGCAAGTGACATGATCGAATCTTGTGTCAAAAGAACCAGGATTGCATTTGAAGTTAAGCTGCAAAAAACCAGTCGATCAACAGATTTTCGAGTCCCACAGTCAATATGCACCATGTTTAATGTTATGGTTGATGCCAAAGCTCAATCAACAAAACTTTGCAGCATGGAAATGGGCCAAGAGCATCAATACCATTCAAAAATAGACGAACTAATTGAAGAAACTGTTAAAGAAATGATAACACTCTTGGTTGCAAAGTTCGTTACTATCTTGGAAGGAGTGCTGGCAAAATTATCCAGATATGACGAAGGGACTTTGTTTTCTTCTTTTCTGTCATTTACCGTGAAGGCAGCTTCCAAATATGTGGATGTACCTAAACCCGGGATGGACGTGGCCGACGCCTACGTGACTTTCGTCCGCCATTCTCAGGATGTCCTGCGTGATAAGGTCAATGAGGAGATGTACATAGAAAGGTTATTTGAT
hsa_circRNA001321	GAGGAATTAGAAGGTCTTCATCTATGTCTTATGTTGATGGCTTCATAGGGACATGGCCCAAAGAGAAAAGATCATCAGTGCATGGCGTATCATTTGATATTTCTTTTGATAAAGAAGATAGTGTACAGAGATCCACTCCAAACCGAGGAATCACTCGTTCTATTAGTAATGAAGGACTTACTCTGAACAACAGTCATGTATCTAAACACATTAGGAAAAATTTGTCCTTCAAGCCAATAAATGGAGAAGAGGAAGCAGAGAGCATTGAAGAAGAACTTAATATAGATTCTCACAGTGACCTCAAATCTTGTGTGCCCCTTAACACAAATGAACTAAATTCTAATGAGAATATTCATTACAAGCTTCCAAATGGAGCTTTACAAAATAGAATACTTCTTGACGAGTTTGGCAATCAGATCGAGACACCAAGCATTGAAGAAGCATTACAAATAATTCATGATACTGAAAAATCTCCTCATACACCTCAGCCAGACCAAATTGCTAATGGCTTCTTTCTTCATAGTCAAGAAATGAGTATCTTAAATTCAAATATCAAGTTAAATCAATCTAGTCCTGATAATGTAACTGATACGAAAGGTGCCTTGAGTCCCATAACTGACAATACTGAAGTAGACACTGGAATTCACGTTCCTTCAGAAGATATTCCTGAAACTATGGACGAAGATTCTTCGTTGAGAGATTATACTGTAAGCTTGGACTCTGACATGGATGATGCATCTAAATTTCTTCAGGATTATGATATTCGAACTGGCAACACCAGGGAAGCTTTGAGTCCTTGTCCAAGTACTGTAAGTACCAAGTCTCAGCCAGGCAGCAGTGCTTCTTCTAGTTCTGGAGTTAAAATGACCAGCTTTGCTGAACAAAAATTCAGGAAACTGAATCATACCGATGGAAAAAGTAGTGGAAGCAGTTCTCAAAAAACTACACCAGAAGGCTCTGAACTTAATATTCCTCATGTGGTTGCTTGGGCACAAATTCCAGAAGAAACAGGGCTTCCACAGGGACGGGACACTACCCAGCTGTTGGCCTCTGAAATGGTGCATCTTAGGATGAAACTAGAAGAAAAGAGGCGTGCTATAGAAGCCCAGAAAAAGAAAATGGAAGCTGCTTTTACCAAACAGAGACAGAAAATGGGAAGGACAGCATTCCTTACTGTAGTGAAAAAGAAAGGGGATGGGATATCTCCTCTACGAGAGGAAGCGGCGGGTGCAGAAGATGAGAAAGTATATACTGATCGAGCAAAAGAAAAGGAATCACAAAAAACTGATGGACAAAGGAGCAAGTCACTGGCAGATATAAAAGAGAGCATGGAGAATCCTCAAGCCAAATGGCTAAAGTCTCCAACTACACCTATTGATCCTGAGAAGCAGTGGAACCTGGCAAGCCCCTCAGAAGAAACTTTAAATGAAGGAGAGATTTTAGAATATACCAAATCCATTGAAAAGTTAAATTCATCCCTGCATTTTCTACAACAAGAAATGCAACGCTTGTCACTTCAGCAGGAGATGTTAATGCAGATGAGAGAGCAACAATCTTGGGTGATTTCACCTCCACAACCCTCTCCACAGAAACAGATTCGAGATTTTAAGCCTTCTAAGCAGGCAGGCCTGTCATCAGCCATTGCACCATTCTCCTCAGACTCCCCTCGTCCTACTCACCCATCTCCACAGTCTTCTAACAGGAAAAGTGCATCTTTTTCTGTTAAAAGTCAAAGGACTCCTAGGCCAAATGAGTTAAAAATAACACCTTTGAATCGAACCTTGACACCTCCTCGGTCTGTGGATAGCCTTCCTCGGTTAAGGAGGTTTTCACCAAGTCAAGTTCCTATTCAAACTAGGTCATTTGTATGTTTTGGGGATGATGGAGAACCTCAGTTAAAGGAATCCAAACCTAAAGAGGAAGTTAAAAAGGAGGAATTGGAATCCAAAGGGACTTTGGAACAGCGTGGACATAATCCAGAAGAAAAGGAAATCAAACCTTTTGAGTCAACAGTCTCTGAAGTCCTATCACTGCCTGTCACAGAGACTGTATGTCTGACACCAAATGAGGACCAATTGAATCAACCCACAGAACCCCCTCCTAAACCCGTTTTCCCACCCACTGCTCCAAAAAATGTTAATCTGATTGAAGTTTCCCTCTCAGATTTGAAACCCCCTGAAAAGGCTGATGTACCTGTTGAAAAATATGATGGAGAAAGTGATAAAGAACAATTTGATGATGACCAGAAAGTATGCTGTGGATTCTTTTTTAAGGATGATCAAAAAGCAGAAAATGATATGGCAATGAAACGGGCAGCTTTGTTGGAGAAAAGATTAAGAAGGGAAAAGGAAACTCAGCTCCGGAAACAACAGTTGGAAGCAGAAATGGAGCATAAGAAGGAGGAAACAAGGCGTAAAACTGAGGAAGAACGTCAGAAGAAAGAAGATGAGAGAGCACGCAGAGAATTTATTAGGCAAGAATATATGAGGCGGAAACAACTGAAATTCTAATGGAAGATATGGATACAGTAATTAAACCCCGTCCTCAAGTAGTAAAACAAAAAAAACAGCGACCAAAATCTATTCACAGAGATCATAGAATCCCCCAAAACACCAATAAAGGGTCCTCCAG
hsa_circRNA003878	GTCAGGATCGTGTGATTGTAAACTAGTCAGGTCAGGGTCGTGTGATTGTAAACTAGTCAGGTCAGGGTCGTGTGATTGTAAACTAGTCAG
hsa_circRNA002085	TGCTGGGATTACAGGCGTGACCATGGCACCGAGAACAATTTTTTGAAATTTAAGTTTTGGTGTTAAAGGTTTGGGTCAAGTTAAGCAGAGCTTGGGCTTGACACATATGTACACACGTGTGTGTGGGTGCGATGTATGTATTCTGCAACTGGCTATGACACCAATGCCCAGATGTCAAGTGGGAAATTTTCCAAGTTCTTGACAGCATCCAAGCATATATACTTTAGGCAGATACTTATATTCTTTGGTCTGGCAATGAGTGAGGAGAATAATAGATGAGACCTTTGGAAACGATGAAAATGATCATTACAGACCCATCCACACTTGATAGTTGGAGCAGTTGTGCCTGGAGGTGGATTGGGAGAACTTCTCTTTCGAGCTTTCTGAAGTTTTCCTTTAAATCAGTTGAGCTATTGATATAAAAATTGTCTCAGAGTCCTAATATGCTTATTATACATTTTGTAGTTGGTTATAGCTCCAAGTGACTCAGTCACCAGAAAAGTCACTTGAAAGTTGGTGTATCTCTACAAAACCTTGGTGAACATTTAAATCACCTTTTTAAATATTACACTCTTCATGGAACTTTACTTTTAGTAATGTCAAACATCTGCCTACAAAATGGAATGTTATTTTACATGTATACTAACTTGTTCTTCAAAATGCAGCACCTCCTTTCACTATACAGACGGTCCTTGACATACACTGGTTCAACTTAAGATTGTGCAAGTTTATTACAAATTTTTCAGGACATAACCTTATCATAAGTCAAGGTCTGAACTTTACGATGGTTTGACGTCAGACTTTTTACTGGGTCTGTCCACGTGTTAAGTACATTTTGAGTTACCATATTTTCTATTTATGATGGGTTTAGTGAAGTGTAACTCTATCATAAGTTGGGGAGCATCTGTGTTGCCAAAACCACTGGAGGGCTACAATATGGCTGGAGGGAATGGAAGAATTTTTCTGGTATATAGAAAGAAGTGAGGCTGACATTTGCAGGCAGAACTGCTGCTTTATCGCAAGGTGACATAGTCTTTTTCCACTTTAAGAGCCTAGTAGCAGTCCCTAGAAATCACTGAAATCATCTTTGAGATATATAAGAGTGTAAGGTTTATATAGGAATCCCTGCAACTTCACACATTTGAGAAGGAACAGGATAGGCCTCCCTTCCTCTGTGGATTCAGGGGCTCCGTAATTATCAAGGGAAGGTATAAGTTTCACATAATACCTACAGGGCCTTTCATTTTCATTTCATGCATACTATTTTACTTAATTTTGAGCATCTTAGAATTGCTTGCTTCAAGTTATAAGTAGATAGTTTTTGAAATTAATTTGCTTCCTAAAGCAATTCATTTATTGTGCTCAGATTTTGCTCACTTGAAAGTCCTATATTCTGTGTAGAACTTGGAATTCTATATAAACAGAACAATGGTTTGAATTGCAAAAAAAGCCCATGATCAGTATCTTAGTTTGCCAATGGCTGGGCATGGTGGCTCATGCCTGTCATCCCAACA
hsa_circRNA003884	GTGTGATTGTAAACTAGTAAGGTCAGGATCGTGTGATTGTAAAGTAGTCAGGTCAGGATCGTGTGATTGTAAACTAGTCAGGTCAGGGTC
hsa_circRNA003876	GTCAGGGTCGTGTGA TTGTAAACTAGTCAG
hsa_circRNA007410	GCAGAGGAAAATATTGACTTATTAGATGATGGCTCTAATTCTTTTGCAACTGACTTGTCATCAGGAACTATTAACCACAAGAAATACATCAAGTTTTCTAAAACAATAGAGAAGGAAATTTCACCGGAAATTAGGAGTTTGAGCCCAGAATATAAAAAAATATTTGAAACATCAATAATCTTTTGTGGAGAAGAAAAGTCCTCTGATTTTTCAGGAGAAAAAAAAGTTGGGAGAAAGAGTTTACAAGTACAACAGCACAGTAAAAGAACTGAGATTATCCCTCCTTTTCTGAAGCTGTCAAAGGAGAAGGTGACAAGGAAAGAAAACTCTTTATGCAAGTTGCCGAATCAGTACAGCGTTCACAAGACTTCATCACCTCTTTGTACATCTTCTGCAATTACTCGGGAAAAGGAAATGCTGTCTAACCTCTACATGACATTATATGATGAAGTAACCCATGGATATTTACACTCAAAAGAATTAAGTGCACTTCATAAAGCCTGTAAAATTTTTAGTAAAATTCGAAGTGGTAAGATTTATGTGAATGATCTTCCAGTGATCCTTTGCATCTTGAGAATTTCTATAAGTGATTTAGAAATGCGACAGGCACTAAAGACTGTTGATATTGATGCATTCCAGGATGCCTTGAAGATTTTCTGTAGGATAAAAGGTGGTCGAGTTTCAACTGATGACGTGTTTGCTGTTTTGGATAGCATGGGTATCCCTATAAACCGTGAAATTTTAGAAGAAGTGACAAAACATACCTATATTGACA
hsa_circRNA007411	AGGAAAATATTGACTTATTAGATGATGGCTCTAATTCTTTTGCAACTGACTTGTCATCAGGAACTATTAACCACAAGAAATACATCAAGTTTTCTAAAACAATAGAGAAGGAAATTTCACCGGAAATTAGGAGTTTGAGCCCAGAATATAAAAAAATATTTGAAACATCAATAATCTTTTGTGGAGAAGAAAAGTCCTCTGATTTTTCAGGAGAAAAAAAAGTTGGGAGAAAGAGTTTACAAGTACAACAGCACAGTAAAAGAACTGAGATTATCCCTCCTTTTCTGAAGCTGTCAAAGGAGAAGGTGACAAGGAAAGAAAACTCTTTATGCAAGTTGCCGAATCAGTACAGCGTTCACAAGACTTCATCACCTCTTTGTACATCTTCTGCAATTACTCGGGAAAAGGAAATGCTGTCTAACCTCTACATGACATTATATGATGAAGTAACCCATGGATATTTACACTCAAAAGAATTAAGTGCACTTCATAAAGCCTGTAAAATTTTTAGTAAAATTCGAAGTGGTAAGATTTATGTGAATGATCTTCCAGTGATCCTTTGCATCTTGAGAATTTCTATAAGTGATTTAGAAATGCGACAGGCACTAAAGACTGTTGATATTGATGCATTCCAGGATGCCTTGAAGATTTTCTGTAGGATAAAAGGTGGTCGAGTTTCAACTGATGACGTGTTTGCTGTTTTGGATAGCATGGGTATCCCTATAAACCGTGAAATTTTAGAAGAAGTGACAAAACATACCTATATTGACAGTGA
hsa_circRNA004558	ACCAATCTGACCTTCGTTGGCTGCGTGGGCATGCTGGATCCTCCGAGAATCGAGGTGGCCTCCTCCGTGAAGCTGTGCCGGCAAGCAGGCATCCGGGTCATCATGATCACTGGGGACAACAAGGGCACTGCTGTGGCCATCTGTCGCCGCATCGGCATCTTCGGGCAGGATGAGGACGTGACGTCAAAAGCTTTCACAGGCCGGGAGTTTGATGAACTCAACCCCTCCGCCCAGCGAGACGCCTGCCTGAACGCCCGCTGTTTTGCTCGAGTTGAACCCTCCCACAAGTCTAAAATCGTAGAATTTCTTCAGTCTTTTGATGAGATTACAGCTATGACTGGCGATGGCGTGAACGATGCTCCTGCTCTGAAGAAAGCCGAGATTGGCATTGCTATGGGCTCTGGCACTGCGGTGGCTAAAACCGCCTCTGAGATGGTCCTGGCGGATGACAACTTCTCCACCATTGTGGCTGCCGTTGAGGAGGGGCGGGCAATCTACAACAACATGAAACAGTTCATCCGCTACCTCATCTCGTCCAACGTCGGGGAAGTTGTCTG

circRNA, circular RNA.

Table IV.

Parental genes corresponding to the differentially expressed circRNAs.

A, upregulated circRNAs

circ_ID	P-value	FC	Chr	Start	End	Str	Loci	Gene list	Description
hsa_circRNA003878	0.003525	15.10051	chr12	2255950	2256039	–	Exon	CACNA1C	Calcium voltage-gated channel subunit α1C
hsa_circRNA003884	0.027306	94.9909	chr12	2256001	2256090	–	Exon	CACNA1C	Calcium voltage-gated channel subunit α1C
hsa_circRNA003876	0.033396	116.6174	chr12	2255950	2255979	–	Exon	CACNA1C	Calcium voltage-gated channel subunit α1C
hsa_circRNA007411	0.042442	295.9099	chr17	47335200	47361525	+	Exon	EFCAB13	EF-hand calcium binding domain 13
hsa_circRNA007410	0.041746	522.6585	chr17	47335196	47361521	+	Exon	EFCAB13	EF-hand calcium binding domain 13
hsa_circRNA002085	0.025361	101.3261	chr10	18508039	18509552	–	Exon	CACNB2	Calcium voltage-gated channel auxiliary subunit β2
hsa_circRNA011785	0.026138	2.935789	chr3	62438104	62499268	–	Exon	CADPS	Ca²⁺ dependent secretion activator
hsa_circRNA001321	0.012686	5.92702	chr1	200847640	200853495	+	Exon	CAMSAP2	Calmodulin regulated spectrin associated protein family member 2

B, downregulated circRNAs

circ_ID	P-value	FC	Chr	Start	End	Str	Loci	GeneList	Description

hsa_circRNA004558	0.007921	0.08415	chr12	110340659	110342448	+	Exon	ATP2A2	ATPase sarcoplasmic/endoplasmic reticulum Ca²⁺ transporting 2

circRNA, circular RNA; FC, fold-change; Chr, chromosome; Str, strand.